Prostate cancer and prostatic diseases

Keyphrases

Publications

2023

Stacy Loeb, Tatiana Sanchez Nolasco, Katherine Siu, Nataliya Byrne, Veda N Giri
Usefulness of podcasts to provide public education on prostate cancer genetics. Prostate cancer and prostatic diseases (2023)
Jacob E Tallman, Christopher J D Wallis, Zhiguo Zhao, Li-Ching Huang, David F Penson, Tatsuki Koyama, Michael Goodman, Ann S Hamilton, Xiao-Cheng Wu, Lisa E Paddock, Antoinette M Stroup, Matthew R Cooperberg, Mia Hashibe, Brock B O'Neil, Sherrie H Kaplan, Sheldon Greenfield, Karen E Hoffman, Daniel A Barocas
Correction to: Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. Prostate cancer and prostatic diseases (2023)
Hae Lin Cho, Subha Perni, Anthony V D'Amico, Kosj Yamoah, Edward Christopher Dee
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging. Prostate cancer and prostatic diseases (2023)
Alberto Martini, Alae Touzani, Elio Mazzone, Mathieu Roumiguié, Giancarlo Marra, Massimo Valerio, Jean Baptiste Beauval, Riccardo Campi, Andrea Minervini, Roderick C N van den Berg, Timo F W Soeterik, Junlong Zhuang, Hongqian Guo, Paolo Gontero, Francesco Montorsi, Alberto Briganti, Giorgio Gandaglia, Guillame Ploussard, null null
Correction to: Overdiagnosis and stage migration of ISUP 2 disease due to mpMRI-targeted biopsy: facts or fictions. Prostate cancer and prostatic diseases (2023)
Jacob E Tallman, Christopher J D Wallis, Zhiguo Zhao, Li-Ching Huang, David F Penson, Tatsuki Koyama, Michael Goodman, Ann S Hamilton, Xiao-Cheng Wu, Lisa E Paddock, Antoinette M Stroup, Matthew R Cooperberg, Mia Hashibe, Brock B O'Neil, Sherrie H Kaplan, Sheldon Greenfield, Karen E Hoffman, Daniel A Barocas
Correction to: Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. Prostate cancer and prostatic diseases (2023)
Athul John, Alicia Lim, Rick Catterwell, Luke Selth, Michael O'Callaghan
Length of positive surgical margins after radical prostatectomy: Does size matter? - A systematic review and meta-analysis. Prostate cancer and prostatic diseases (2023)
Luca Afferi, Mattia Longoni, Marco Moschini, Giorgio Gandaglia, Alicia K Morgans, Richard Cathomas, Agostino Mattei, Alberto Breda, Roberto Mario Scarpa, Rocco Papalia, Cosimo De Nunzio, Francesco Esperto
Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy. Prostate cancer and prostatic diseases (2023)
Renée Hogenhout, Sebastiaan Remmers, G J L H Geert van Leenders, Monique J Roobol
The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates. Prostate cancer and prostatic diseases (2023)
David J Carpenter, Joseph K Salama, W Robert Lee, Matthew J Boyer
Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415. Prostate cancer and prostatic diseases (2023)
Julie A Szymaniak, Samuel L Washington, Janet E Cowan, Matthew R Cooperberg, Peter E Lonergan, Hao G Nguyen, Maxwell V Meng, Peter R Carroll
The natural history of a delayed detectable PSA after radical prostatectomy. Prostate cancer and prostatic diseases (2023)
Julie A Szymaniak, Samuel L Washington, Janet E Cowan, Matthew R Cooperberg, Peter E Lonergan, Hao G Nguyen, Maxwell V Meng, Peter R Carroll
The natural history of a delayed detectable PSA after radical prostatectomy. Prostate cancer and prostatic diseases (2023)
David Eldred-Evans, Mathias Winkler, Natalia Klimowska-Nassar, Paula Burak, Martin John Connor, Francesca Fiorentino, Emily Day, Derek Price, Martin Gammon, Henry Tam, Heminder Sokhi, Anwar R Padhani, Hashim Uddin Ahmed
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study. Prostate cancer and prostatic diseases (2023)
Mike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, Christoph Würnschimmel, Zhe Tian, Shahrokh F Shariat, Fred Saad, Derya Tilki, Markus Graefen, Luis A Kluth, Alberto Briganti, Philipp Mandel, Francesco Montorsi, Felix K H Chun, Pierre I Karakiewicz
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate cancer and prostatic diseases (2023)
Julie A Szymaniak, Samuel L Washington, Janet E Cowan, Matthew R Cooperberg, Peter E Lonergan, Hao G Nguyen, Maxwell V Meng, Peter R Carroll
The natural history of a delayed detectable PSA after radical prostatectomy. Prostate cancer and prostatic diseases (2023)
Giampaolo Siena, Francesco Sessa, Luca Cindolo
Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate. Prostate cancer and prostatic diseases (2023)
Simone Albisinni, Romain Diamand
Understanding biochemical recurrence after radical prostatectomy: trust biology, not a number. Prostate cancer and prostatic diseases (2023)
Ting Martin Ma, Felix Y Feng, Seth A Rosenthal, Matthew B Rettig, Ann C Raldow, Daniel E Spratt, Michael Xiang, Amar U Kishan
Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era. Prostate cancer and prostatic diseases (2023)
Tommaso Cai, Jakhongir Alidjanov, Ivan Palagin, José Medina-Polo, J Curtis Nickel, Florian M E Wagenlehner
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): look to the future. Prostate cancer and prostatic diseases (2023)
Gillian Gresham, Carolina Raines, Arash Asher, Stephen J Freedland, Celina H Shirazipour, Alix G Sleight
Can high-intensity interval training impact tumor suppression and inflammatory response in prostate cancer survivors? Prostate cancer and prostatic diseases (2023)
Hannes Cash, Martin Schostak
Correction to: The role of PSA density in the MRI pathway for prostate cancer diagnostics. Prostate cancer and prostatic diseases (2023)
Yusuf Liadi, Taaliah Campbell, Precious Dike, Maxine Harlemon, Bethtrice Elliott, Valerie Odero-Marah
Prostate cancer metastasis and health disparities: a systematic review. Prostate cancer and prostatic diseases (2023)
Renée Hogenhout, Sebastiaan Remmers, G J L H Geert van Leenders, Monique J Roobol
The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates. Prostate cancer and prostatic diseases (2023)
Gloria Cecilia Galván, Sanjay Das, James Percy Daniels, Nadine A Friedrich, Stephen J Freedland
Working hard or hardly working? A brief commentary of latest research on exercise and prostate cancer. Prostate cancer and prostatic diseases (2023)
Gloria Cecilia Galván, James Percy Daniels, Nadine A Friedrich, Sanjay Das, Stephen J Freedland
A healthy diet, a healthy prostate? A brief commentary on the latest research on diet and prostate cancer. Prostate cancer and prostatic diseases (2023)
Massimiliano Creta, Celeste Manfredi, Davide Arcaniolo, Marco De Sio, Nicola Longo, Cosimo De Nunzio, Ferdinando Fusco
Mobile health: a promising tool for the management of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate cancer and prostatic diseases (2023)
Giampaolo Siena, Francesco Sessa, Luca Cindolo
Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate. Prostate cancer and prostatic diseases (2023)
Alberto Martini, Guillaume Ploussard
Reply to: Fact, overdiagnosis cannot be evaluated by comparing histological grading of prostate biopsy to prostatectomy specimen. Prostate cancer and prostatic diseases (2023)
Jacob E Tallman, Christopher J D Wallis, Li-Ching Huang, Zhiguo Zhao, David F Penson, Tatsuki Koyama, Ralph Conwill, Michael Goodman, Ann S Hamilton, Xiao-Cheng Wu, Lisa E Paddock, Antoinette Stroup, Matthew R Cooperberg, Mia Hashibe, Brock B O'Neil, Sherrie H Kaplan, Sheldon Greenfield, Daniel A Barocas, Karen E Hoffman
Correction to: Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. Prostate cancer and prostatic diseases (2023)
Frank A Schumacher, Irene B Helenowski, Zequn Sun, Laura B Oswald, Brian D Gonzalez, Kelvin A Moses, James T Benning, Alicia K Morgans
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction. Prostate cancer and prostatic diseases (2023)
Antonio Cicione, Antonio Nacchia, Alessandro Guercio, Carmen Gravina, Antonio Franco, Maria Chiara Grimaldi, Giorgia Tema, Riccardo Lombardo, Andrea Tubaro, Cosimo De Nunzio
Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries. Prostate cancer and prostatic diseases (2023)
Massimiliano Creta, Celeste Manfredi, Davide Arcaniolo, Marco De Sio, Nicola Longo, Cosimo De Nunzio, Ferdinando Fusco
Mobile health: a promising tool for the management of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate cancer and prostatic diseases (2023)
Tommaso Cai
Antimicrobial prophylaxis: To do or not to do? This is the question. Prostate cancer and prostatic diseases (2023)
Harshit Garg, Furkan Dursun, Fadi Alsayegh, Hanzhang Wang, Shenghui Wu, Michael A Liss, Dharam Kaushik, Robert S Svatek, Ahmed M Mansour
Revisiting current National Comprehensive Cancer Network (NCCN) high-risk prostate cancer stratification: a National Cancer Database analysis. Prostate cancer and prostatic diseases (2023)
Angela Y Jia, Ana P Kiess, Qiubai Li, Emmanuel S Antonarakis
Radiotheranostics in advanced prostate cancer: Current and future directions. Prostate cancer and prostatic diseases (2023)
Christian Thomas
Perilesional sampling: the new standard for imaging-targeted prostate biopsies? Prostate cancer and prostatic diseases (2023)
Aaron Brant, Patrick Lewicki, Stephen Rhodes, Camilo Arenas-Gallo, Mary O Strasser, Alec Zhu, Lee Ponsky, Jonathan E Shoag
Price transparency of prostate cancer care in the United States: An analysis of pricing and disclosure following the centers for medicare and medicaid mandate. Prostate cancer and prostatic diseases (2023)
Andrea Fuschi, Antonio Luigi Pastore, Yazan Al Salhi, Alessia Martoccia, Cosimo De Nunzio, Giorgia Tema, Onofrio Antonio Rera, Flavia Carbone, Anastasios D Asimakopoulos, Manfredi Bruno Sequi, Fabio Maria Valenzi, Paolo Pietro Suraci, Silvio Scalzo, Francesco Del Giudice, Stefano Nardecchia, Giorgio Bozzini, Alessandro Corsini, Alessandro Sciarra, Antonio Carbone
The impact of radical prostatectomy on global climate: a prospective multicentre study comparing laparoscopic versus robotic surgery. Prostate cancer and prostatic diseases (2023)
David-Dan Nguyen, Tiange Li, Roseanne Ferreira, Mohamad Baker Berjaoui, Anna-Lisa V Nguyen, Bilal Chughtai, Kevin C Zorn, Naeem Bhojani, Dean S Elterman
Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation. Prostate cancer and prostatic diseases (2023)
Mohammad R Siddiqui, Eric V Li, Sai K S R Kumar, Anna Busza, Jasmine S Lin, Ashorne K Mahenthiran, Jonathan A Aguiar, Parth V Shah, Brandon Ansbro, Jordan M Rich, Soliman A S Moataz, Mary-Kate Keeter, Quan Mai, Xinlei Mi, Jeffrey J Tosoian, Edward M Schaeffer, Hiten D Patel, Ashley E Ross
Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men. Prostate cancer and prostatic diseases (2023)
Riccardo Lombardo, Cosimo De Nunzio
Nomograms in PCa: where do we stand. Prostate cancer and prostatic diseases (2023)
Cosimo De Nunzio, Riccardo Lombardo
Best of 2022 in prostate cancer and prostatic diseases. Prostate cancer and prostatic diseases (2023)
John M Masterson, Michael Luu, Aurash Naser-Tavakolian, Stephen J Freedland, Howard M Sandler, Zachary S Zumsteg, Timothy John Daskivich
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer. Prostate cancer and prostatic diseases (2023)

volume 26, number 1, 2023

Frank A Schumacher, Irene B Helenowski, Zequn Sun, Laura B Oswald, Brian D Gonzalez, Kelvin A Moses, James T Benning, Alicia K Morgans
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction. Prostate cancer and prostatic diseases 26 (1) (2023)
Cosimo De Nunzio, Riccardo Lombardo
Best of 2022 in prostate cancer and prostatic diseases. Prostate cancer and prostatic diseases 26 (1) (2023)
Frank A Schumacher, Irene B Helenowski, Zequn Sun, Laura B Oswald, Brian D Gonzalez, Kelvin A Moses, James T Benning, Alicia K Morgans
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction. Prostate cancer and prostatic diseases 26 (1) (2023)
Frank A Schumacher, Irene B Helenowski, Zequn Sun, Laura B Oswald, Brian D Gonzalez, Kelvin A Moses, James T Benning, Alicia K Morgans
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction. Prostate cancer and prostatic diseases 26 (1) (2023)
Frank A Schumacher, Irene B Helenowski, Zequn Sun, Laura B Oswald, Brian D Gonzalez, Kelvin A Moses, James T Benning, Alicia K Morgans
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction. Prostate cancer and prostatic diseases 26 (1) (2023)
Cosimo De Nunzio, Riccardo Lombardo
Best of 2022 in prostate cancer and prostatic diseases. Prostate cancer and prostatic diseases 26 (1) (2023)
Cosimo De Nunzio, Riccardo Lombardo
Best of 2022 in prostate cancer and prostatic diseases. Prostate cancer and prostatic diseases 26 (1) (2023)
Cosimo De Nunzio, Riccardo Lombardo
Best of 2022 in prostate cancer and prostatic diseases. Prostate cancer and prostatic diseases 26 (1) (2023)